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Introduction 
G protein-coupled receptors (GPCRs) are physiologically important transmembrane 
signaling proteins that trigger intracellular responses upon binding of extracellular ligands. 
Despite recent breakthroughs in GPCR crystallography1-3, the details of ligand-induced signal 
transduction are not well understood due to missing dynamical information. In principle, such 
information can be provided by NMR4, but so far only limited data of functional relevance on 
few side chain sites of eukaryotic GPCRs have been obtained5-9. Here, we show that receptor 
motions can be followed at virtually any backbone site in a thermostabilized mutant of the 
turkey β1-adrenergic receptor (β1AR)10-12. Labeling with 15N-valine in a eukaryotic expression 
system provides over twenty resolved resonances that report on structure and dynamics in six 
ligand complexes and the apo form. The response to the various ligands is heterogeneous in 
the vicinity of the binding pocket, but gets transformed into a homogeneous readout at the 
intracellular side of helix 5 (TM5), which correlates linearly with ligand efficacy for the G 
protein pathway. The effect of several pertinent, thermostabilizing point mutations was 
assessed by reverting them to the native sequence. Whereas the response to ligands remains 
largely unchanged, binding of the G protein mimetic nanobody NB80 and G protein activation 
are only observed when two conserved tyrosines (Y227 and Y343) are restored. Binding of 
NB80 leads to very strong spectral changes throughout the receptor including the extracellular 
ligand entrance pocket. This indicates that even the fully thermostabilized receptor undergoes 
activating motions in TM5, but the fully active state is only reached in presence of Y227 and 
Y343 by stabilization with a G protein-like partner. The combined analysis of chemical shift 
changes from the point mutations and ligand responses identifies crucial connections in the 
allosteric activation pathway and presents a general experimental method to delineate signal 
transmission networks at high resolution in GPCRs. 
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Results and discussion 
A thermostabilized, detergent-resistant mutant of β1AR10-12 (TS-β1AR; see Methods) was 
selectively labeled with 15N valine and produced in insect cells without further chemical 
modifications. Its 28 valine residues are homogeneously distributed across the receptor 
(Extended Data Figure 1) at locations suitable to sense ligand binding and receptor activation. 
Although resonances of main chain atoms are considerably more difficult to observe than 
those of mobile side chains of surface residues, they are expected to be better reporters of 
functional, long-range backbone motions. We succeeded to obtain well-resolved TROSY 
spectra of the valine 1H-15N backbone resonances of detergent-solubilized TS-β1AR in its apo 
form and in complexes with six ligands (Extended Data Figure 1) ranging in their efficacy 
from antagonists to agonists (Extended Data Table 1). Despite the absence of deuteration and 
very short T2 relaxation times (~4 ms for 1HN), 26 valine resonances could be observed with 
sufficient sensitivity and resolution. Distinct and reversible chemical shift changes were 
detected for many valines after ligand exchange. 16 valines were assigned unambiguously and 
5 tentatively using spectra from 18 point mutants, as well as further spectral and structural 
information (Extended Data Table 2). 
Many valine residues in the vicinity of the ligand binding pocket could be assigned, 
showing chemical shift changes that report on the ligand functional groups (Figure 1). 
Remarkably, residue V172(4.56) (the number in parenthesis corresponds to the Ballesteros-
Weinstein numbering system13), which is located close to the ligand aromatic head group, 
exhibits an unusual 15N chemical shift of ~105–110 ppm (Extended Data Figure 1, 2 and 
Figure 1C). This anomaly seems caused by a distorted backbone geometry, which is 
presumably conserved among adrenergic receptors and results from a missing hydrogen bond 
to the proline at position 176(4.60) (Extended Data Figure 2). Instead, the carbonyl of 
V172(4.56) participates in a water-mediated hydrogen bond network, which connects the 
ligand binding site, TM3, TM4, TM5, and TM612,14. Seemingly as a result of these 
interactions, the V172(4.56) 1H-15N resonances cluster according to the substitution patterns of 
the ligand head group (Figure 1C): one cluster is observed for the partial agonists/antagonists 
cyanopindolol, alprenolol and carvedilol, which have larger head groups with ortho- and/or 
meta-substitutions; a second cluster is observed for the agonists isoprenaline and dobutamine, 
which bear a meta- and para-substituted catechol ring. We attribute the distinct chemical shifts 
for isoprenaline or dobutamine to the loss of a coordinated water caused by specific hydrogen 
bond interactions between their catechol moieties and the side chain of S215(5.461) (Extended 
Data Figure 2D). 
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Remarkably, the resonance positions of V172(4.56) in complex with the antagonist 
atenolol strongly differ from the already described complexes and the apo form: considerable 
1HN  (>0.4 ppm) and 15N (>4 ppm) upfield shifts indicate, respectively, a further weakening of 
the main chain hydrogen bond V172(4.56)HN···I168(4.52)O and a stronger kink of the 
backbone. This rearrangement is likely due to the "insertion" of the para-acetamide group of 
the ligand head between residues S215(5.461) and V172(4.56) (Extended Data Figure 2D). 
This will lead to a substantial disruption of the TM3-TM4-TM5 interface, thereby precluding 
receptor activation, in agreement with atenolol’s inverse agonist pharmacology. Thus, the 
amide chemical shifts of V172(4.56) constitute a very sensitive readout for the state of this 
water-mediated, inter-helical activation switch. 
The 1H-15N chemical shifts of further residues in the vicinity of the binding pocket report 
on additional characteristics of the ligands. V314(6.59) and V202(ECL2) are located at the 
extracellular surface of the receptor in a “vestibule” next to the entry/exit pathway of the 
orthosteric binding site15,16. The resonances of these residues are either severely broadened or 
undetectable in the absence of ligands, whereas they are observable in the presence of ligands 
(Figure 1D and Extended Data Figure 3). A line shape analysis for V314(6.59) (Extended Data 
Figure 4) indicates that this extracellular part of the receptor undergoes micro- to millisecond 
motions in the apo form, which are quenched by ligand binding. This is consistent with results 
on β2AR, which suggest that high-affinity ligands stabilize the conformation of ECL2 and 
ECL35. The ligand-induced shifts of the V314 resonance correlate strongly  (r2 = 0.95) with 
the reported ligand affinity17 (Figure 1D). Interestingly, the resonances of V314(6.59) in the 
apo form and in high-affinity ligand complexes are very close. This may indicate that the high-
affinity ligand complexes mimic the average apo conformation. Finally, the 1H-15N chemical 
shifts of V125(3.36) at the bottom of the binding site and of V103(2.65) close to the ligand tail 
reveal additional trends (Figure 1E): the chemical shifts of V125 correlate with the depth of 
ligand insertion towards the central part of TM3 (r2 = 0.81), whereas those of V103 correlate 
with the volume of the ligand tail (r2 = 0.90). 
As compared to inactive β2AR, complexes of activated β2AR with either G protein2 or the 
G protein-mimicking nanobody NB809,18 show large movements at the intracellular sides of 
TM5, TM6 and their intervening loop ICL3, which form the binding site for the G protein. 
These conformational changes are expected to be conserved throughout the GPCR family19. 
Four valine residues could be assigned in this region of TS-β1AR: V226(5.57), V230(5.61), 
V280(6.25), and V298(6.43) (Figure 2). In contrast to the chemical shift changes in the 
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vicinity of the ligand binding pocket, which depend strongly on the ligand chemistry, the shifts 
of the TM5 residues observed in this region report on ligand efficacy. This effect is most 
prominent for residue V226(5.57), for which the 1H-15N resonances fall on one line from 
antagonists to agonists (Figure 2A). The chemical shifts for the different ligands correlate very 
strongly (r2 = 0.89) with their reported17 efficacies for Gs signaling (Extended Data Table 1). 
This highly linear effect suggests that the receptor filters the diverse input signals from the 
various ligands to a unified and precise structural response on TM5, which can be read out by 
the chemical shifts of V226(5.57). Interestingly, the V226(5.57) atenolol peak is situated at a 
position corresponding to lower efficacy than for the apo receptor. This gives direct structural 
evidence of atenolol’s inverse agonist action, which reduces the activation relative to the basal 
level of the apo receptor. 
Current high-resolution structures of β1AR do not show significant changes between 
antagonist- and agonist-bound forms (Figure 2B, top panel). The decrease of the V226(5.57) 
1HN chemical shift by about 0.2 ppm from the agonist isoprenaline to the antagonist atenolol 
indicates a lengthening of the V226(5.57)-HN···I222(5.53)-O hydrogen bond by about 0.05 Å20. 
This small, but clearly NMR-detectable length variation is below the resolution limit of 
current GPCR structures (Supplementary Information Text 1), but may indicate the start of 
TM5 bending towards the active conformation as observed in the G protein-bound form of 
β2AR (Figure 2B). Remarkably, this response to agonists occurs even in the thermostabilized 
receptor TS-β1AR. Albeit reduced in absolute size as compared to V226(5.57), V230(5.61) 
displays similar linear chemical shift changes as a function of ligand efficacy for the Gs 
pathway (Figure 2C). As this residue is located one helical turn further towards the cytoplasm, 
the detected conformational change is not just local, but spans a certain length in TM5. 
Compared to V226(5.57) and V230(5.61) in TM5, the chemical shift response to ligands 
is much less pronounced for V298(6.43) and in particular V280(6.25) at the intracellular side 
of TM6 (Figure 2C). This suggests that agonist binding to the TS-β1AR does not induce the 
large conformational change in TM6 observed in the activated β2AR-G-protein2 or β2AR-
NB8018 complexes. However, G protein activation upon agonist binding has been reported for 
other less thermostabilized β1AR constructs17, indicating that they can still be activated, albeit 
at low levels. Thus we reverted the mutations most likely to interfere with the activation 
mechanism in TS-β1AR, i.e. I129(3.40)V in the connector switch15, Y227(5.58)A in TM521,22, 
and Y343(7.53)L in the NPxxY motif of TM714,22 to the native residues. These reverse mutants 
were then tested for G protein activation and the NMR response in TM6. A summary of the 
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results is given in Extended Data Table 3. The original TS-β1AR, the single mutants TS-
β1ARV129I, TS-β1ARA227Y, and TS-β1ARL343Y as well as the double mutant TS-β1ARV129I/A227Y 
showed no detectable G protein activation upon isoprenaline binding (Extended Data Figure 
5). However, G protein activation was detectable for the least thermostable TS-β1ARA227Y/L343Y 
double mutant (Tm reduced by 11 ˚C relative to TS-β1AR), which recovers the conserved 
tyrosines in TM5 and TM7 that are known to stabilize the active state of rhodopsin22. None of 
the reverse mutants showed major changes in the NMR spectra of various ligand complexes as 
compared to the original TS-β1AR (Extended Data Figure 6). In particular, residues 
V298(6.43) and V280(6.25) at the intracellular side of TM6 did not show an increased 
response to agonists. This is in agreement with recent DEER and 19F-NMR data showing that 
agonists alone do not fully stabilize the active state of TM6 in β2AR9. Interestingly, the 
V129(3.40)I and the V129(3.40)I/A227(5.58)Y mutations shifted the 1H-15N resonances of 
V226(5.57) towards a more active (i.e. bent) state of TM5 in both the atenonol- and 
isoprenaline-bound forms (Extended Data Figure 6B), thereby given direct experimental 
evidence for an allosteric activation pathway spanning about 13 Å from I129(3.40) on TM3 to 
V226(5.57) on TM5. 
With the exception of rhodopsin23, the stabilization of fully active GPCR conformations 
seems to require binding of an agonist and an intracellular partner8,9. Indeed, when both the 
agonist isoprenaline and the G protein-mimicking nanobody NB8018 were added to TS-
β1ARA227Y/L343Y, very large chemical shift responses for many valine residues in TM3-6 were 
observed, whereas no change was observed for several valines in TM1, 2, and 7 (Extended 
Data Figure 7). This very strong response extends even to the extracellular residue 
V314(6.59), providing evidence of a long-distance connection from the G protein binding site 
to the ligand entry site. The strong chemical shift changes are reverted when the partial 
agonist/antagonist cyanopindolol is added to the isoprenaline-TS-β1ARA227Y/L343Y-NB80 
complex. The spectrum then becomes identical to that of the “pure” cyanopindolol-TS-
β1ARA227Y/L343Y complex (Extended Data Figure 7A), indicating that cyanopindolol replaces 
isoprenaline and causes the release of NB80. In agreement with the G protein activation data, 
the isoprenaline-bound original TS-β1AR and the mutants TS-β1ARA227Y and TS-β1ARL343Y did 
not show binding of NB80 in the NMR spectra. Moreover, supplementing NB80 to the 
ultrastable TS-β1AR did not change its affinity for isoprenaline (Extended Data Figure 7B), 
whereas it caused a hundred-fold affinity increase for TS-β1ARA227Y/L343Y and the truncated 
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native turkey β1AR receptor (tβtrunc)17. This increase is identical to data for β2AR18 and shows 
the energetic coupling between the NB80 and agonist binding also for β1AR. 
In combination, these data prove that agonist binding, even in the absence of a G protein-
mimic, induces or stabilizes initial changes in the conformational equilibrium of TM5 towards 
the conformation observed in the G protein complex of β2AR. Remarkably, these 
rearrangements occur in all thermostabilized forms of β1AR. However, a full shift of the 
equilibrium towards such an active conformation including allosteric changes at the 
extracellular side occurs only when G protein or its mimetic NB80 is bound. This process 
requires the presence of both Y227(5.58) and Y343(7.53), which significantly reduce the 
thermal stability. Different active conformations may be reached for non-G protein effectors 
such as β-arrestin. 
The possibility to detect NMR signals at many receptor sites in response to ligand binding 
and point mutations provides an experimental method to trace allosteric signaling paths. 
Figure 3 shows examples of these pathways, derived from the response to the ligands atenolol 
and isoprenaline and the single point mutations V129(3.40)I, A227(5.58)Y, and L343(7.53)Y. 
Choosing a cutoff of 0.05 ppm for the resulting combined 1H, 15N chemical shift change 
(Figure 3A, red line), long-range (>10 Å) connections become evident throughout the receptor 
(Figure 3B and C). Whereas detected ligand signals radiate broadly to almost all helices, the 
point mutants give evidence of smaller interaction networks connecting TM3 to TM4/5, TM5 
to TM3/4/6, as well as TM7 to TM2/3 (Figure 3B,C). Interestingly, the TM2/TM7 network 
appears to be only weakly connected to the TM3-6 network. Together, these data provide 
experimental evidence at high resolution of an extensive signal transduction network that 
connects the ligand binding site to the intracellular sides of TM5, TM6, and TM7. Such a 
network of loosely coupled allosteric connections has been postulated previously for β2AR 
based on molecular dynamics simulations24. 
In summary, we have shown that highly resolved solution NMR backbone spectra can be 
obtained for a eukaryotic GPCR. The NMR observations delineate the allosteric signaling 
pathways and comprehensively connect many previous experimental and theoretical 
observations, which may ultimately allow to understand the dynamic mechanisms of GPCRs 
at the atomic level. 
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Methods 
β1AR constructs 
The TS-β1AR mutant was derived from the turkey β1AR44-m23 mutant used in 
crystallographic studies25 by adding three additional thermostabilizing mutations (I129V, 
D322K, and Y343L) and a neutral mutation (D200E) from the ultra-stable β1AR-JM3 
mutant11. As compared to the wild type, TS-β1AR contains truncations at the N- and C-termini 
and intracellular loop (ICL3), a total of nine thermostabilizing point mutations, three further 
point mutations as well as a C-terminal hexahistidine tag (Extended Data Figure 1). The final 
TS-β1AR sequence is 
MGAELLSQQWEAGMSLLMAL VVLLIVAGNVLVIAAIGSTQ RLQTLTNLFITSLACADLVV 
GLLVVPFGATLVVRGTWLWG SFLCELWTSLDVLCVTASVE TLCVIAIDRYLAITSPFRYQ 
SLMTRARAKVIICTVWAISA LVSFLPIMMHWWRDEDPQAL KCYQDPGCCEFVTNRAYAIA 
SSIISFYIPLLIMIFVALRV YREAKEQIRKIDRASKRKTS RVMLMREHKALKTLGIIMGV 
FTLCWLPFFLVNIVNVFNRD LVPKWLFVAFNWLGYANSAM NPIILCRSPDFRKAFKRLLA 
FPRKADRRLHHHHHH. 
Additional valine-to-alanine or isoleucine point mutations were introduced into TS-β1AR 
for NMR assignment purposes. All constructs were made using the QuikChange site-directed 
mutagenesis method (Agilent). Baculovirus for insect cell expression was generated using the 
Bac-to-Bac system (Invitrogen). 
β1AR expression and purification 
All β1AR constructs were expressed in baculovirus-infected insect cells as described26. 
Selective labeling by 15N-valine was achieved by growing cells on unlabeled serum-free insect 
cell medium (InsectXpress, Lonza) and then exchanging into custom-made serum-free 
medium (SF4, BioConcept) devoid of valine and yeast extract, to which 100 mg/L 15N-valine 
were supplemented. Virus was added immediately after the medium exchange. The culture 
was harvested at 48 or 72 hr post infection. 
After cell lysis, the membrane fraction was separated from the lysate via 
ultracentrifugation and subsequently solubilized with 2 % n-decyl-β-D-maltopyranoside (DM, 
Anatrace). The solubilized membrane fraction was then purified by nickel ion affinity 
chromatography followed by alprenolol ligand affinity chromatography. The active receptor 
was eluted with buffer (20 mM TRIS, 350 mM NaCl, 0.1 % DM, pH 7.5) containing either 
atenolol (1 mM) or alprenolol (0.1 mM). Final yields of detergent-solubilized receptor were 
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1.5 mg/L of cell culture. The molecular weight of the receptor-detergent complex was 
estimated as ~100 kDa by static light scattering. 
Thermal shift assays of mutant receptors 
Detergent-solubilized, purified apo TS-β1AR and reverse-mutation receptors for thermal 
stability assays were obtained from their atenolol-bound form by washing with buffer devoid 
of ligand on a HiTrap SP HP (GE Healthcare) column. Their thermal stability was determined 
by the microscale fluorescent stability assay for binding of the thiol-specific fluorochrome N-
[4-(7-diethylamino-4-methyl-3-coumarinyl)phenyl]maleimide (CPM)27 in a Rotor-Gene Q 
(QIAGEN) real-time PCR cycler using 1 µg of receptor in 20 mM TRIS, 350 mM NaCl, 0.1 % 
DM, pH 7.5 and a heating rate of 2 K/min. 
NMR experiments 
NMR samples were prepared in Shigemi tubes as 250 µl volumes of typically 100 µM 
receptor, 1 mM ligand (except for apo form), 20 mM TRIS, 100 mM NaCl, 0.1 % DM, 5 % 
D2O, pH 7.5. For isoprenaline or dobutamine, 2 mM of sodium L-ascorbate were 
supplemented as anti-oxidant. All solution NMR measurements were carried out on a 
800 MHz or a 900 MHz Bruker Avance III spectrometer equipped with a cryogenic probe at 
304 K. 2D 1H,15N TROSY (transverse relaxation-optimized spectroscopy) spectra were 
recorded with total acquisition periods of 16 ms (15N) and 43 ms (1H) with typical total 
experimental times of 24-48 h. As compared to a standard TROSY pulse sequence, the 1H-15N 
INEPT delays were set to 3 ms to reduce magnetization losses from relaxation. 
Assignment procedure 
To obtain sequence-specific assignment information, we initially attempted to detect 
HNCO and HNCA correlations on samples additionally labeled with 13C at specific backbone 
sites28. However, due to low sensitivity, only very few correlations were observable. 
Therefore, assignments were obtained from a combination of information from TROSY 
spectra recorded on 18 TS-β1AR valine point mutants with different ligands, four HN(CO) 
correlations and five distinct structure-based chemical shift predictions (Extended Data Table 
2). 
Ligand exchange experiments 
Receptor complexes with different ligands were generated by sequential exchange 
according to increasing ligand affinity, i.e. in the sequence atenolol-isoprenaline-dobutamine-
alprenolol or alprenolol-carvedilol-cyanopindolol. For exchange, the sample was washed three 
times with buffer devoid of ligand at 10-fold dilution in Amicon Ultra 50 kDa cutoff 
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concentrators. Subsequently, the sample was washed again twice with buffer containing 
100 µM new ligand, separated by a period of 1 h incubation. Final concentrations of the 
ligands were adjusted to 1 mM. Apo receptor was generated from the atenolol complex by six 
washing steps of 10-fold dilution in ligand-free buffer using a 1 h incubation period for the last 
three steps. 
NMR NB80 binding experiment 
Binding of NB80 to β1AR mutants was assessed using TROSY and 1D proton NMR 
spectra. These spectra were recorded on the β1AR mutants (TS-β1AR: 132 µM, TS-β1ARA227Y: 
120 µM, TS-β1ARL343Y: 110 µM, and TS-β1ARA227Y/L343Y: 120 µM) in the presence of saturating 
amounts (1 mM) of the agonist isoprenaline before and immediately after addition of an 
equimolar (relative to the receptor) amount of NB80. For TS-β1ARA227Y/L343Y additional spectra 
were recorded after a further addition of the partial agonist cyanopindolol (1 mM) to the 
already present isoprenaline and NB80. 
Scintillation proximity assay with 3H-dihydroalprenolol 
For pharmacological binding assays membranes were prepared from SF9 insect cells as 
described previously26. The total protein content of the membranes was estimated by A280 
measurements using an average extinction coefficient of 1.0 per mg/ml. All assays were 
carried out in 96-well plates at 200 μg/ml total protein in membranes and 2 mg/ml WGA-YSi 
beads (Perkin-Elmer) in a 100 μl total volume per well. Samples were equilibrated at room 
temperature for at least 16 h. KD values for the radioactive ligand 3H-dihydroalprenolol (3H-
DHA) were determined by titrating 3H-DHA from 0.032 to 100 nM. Non-specific binding was 
determined in presence of 1 μM S-propanolol to block the ligand binding site. Competition 
assays were performed in the presence of 20 nM 3H-DHA (hot ligand) and increasing 
concentrations of the competitor (cold ligand). Dilutions of alprenolol, atenolol, 
cyanopindolol, dobutamine and isoprenaline were made with phosphate buffered saline (PBS, 
Biochrom, Germany). Due to the limited solubility of carvedilol in water, stock dilutions of 
carvedilol were prepared in DMSO. The final concentration of DMSO in the samples was 5 %. 
To test the effect of NB80 binding on the affinities (IC50) of isoprenaline for various receptor 
mutants, the competition assays were also carried out in the presence of saturating 
concentrations of NB80 (10 μM). IC50 values were determined by fitting the measured 
radioactive counts per minute  𝐶𝑃𝑀(𝑋) at a specific concentration 𝑋 of the competitor to the 
equation  𝐶𝑃𝑀(𝑋) = !"#!"#!!"#!"#!! !!"!" + 𝐶𝑃𝑀!"# , where  𝐶𝑃𝑀!"#  and 𝐶𝑃𝑀!"#  are maximal 
and minimal counts of the assay, respectively. The fits were carried in MATLAB 
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(MathWorks, www.mathworks.com) with Monte-Carlo estimation of errors. Ki values were 
calculated from the obtained IC50 values according to the formula 𝐾! = !"!"!! !!! where A is the 
concentration of the radioactive ligand and Kd is its affinity for the receptor determined in the 
direct binding experiment. 
G protein activation assay 
G protein activation was measured on purified β1AR mutants reconstituted with 
MSP1E3D129 into POPC/POPG nanodiscs. MSP1E3D1 was expressed and purified as 
described29 and cleaved with TEV protease. 1-palmitoyl-2-oleoyl-sn-glycero-3-
phosphocholine (POPC, Avanti Polar Lipids) and 1-palmitoyl-2-oleoyl-sn-glycerol-3-
phospho-(1’-rac-glycerol) sodium salt (POPG, Avanti Polar Lipids) were solubilized at a ratio 
of 1:1.5 (w/w) POPG/POPC in ND buffer (20 mM HEPES pH 8, 100 mM NaCl, 1 mM 
EDTA) with 50 mM sodium cholate (Sigma-Aldrich) at 4 °C. 133.3 μM MSP1E3D1 was 
incubated with 8 mM solubilized POPC/POPG and 10 μM purified β1AR in ND buffer with a 
final concentration of 24 mM sodium cholate for 1 h at 4 °C. Nanodiscs containing the 
receptor were separated from empty nanodiscs using a cobalt-chelating resin. The 
heterotrimeric G protein was prepared by incubating 10 μM recombinant Gαi1 and 10 μM 
native Gβγt in activation buffer (25 mM HEPES pH 7.5, 150 mM NaCl, 2 mM MgCl2, 1 mM 
DTT) for 30 min at 4 °C. 
G protein activation was detected by the change in tryptophan fluorescence caused by the 
exchange of GDP for GTPγS, associated conformational changes in the Gα subunit and its 
dissociation from the Gβγ subunit of the heterotrimeric G protein30. All measurements were 
carried out on a Varian Cary Eclipse fluorescence spectrophotometer (λex = 295 nm, λem = 340 
nm, 1.5 nm excitation slit, 20 nm emission slit, 2 s averaging time, 15 s cycle time) using final 
sample volumes of 1 ml in 10x4 mm cuvettes (Hellma, CH) and magnetic stirrers at 20 °C. 
Prior to activation, the fluorescence intensity baseline was recorded with 100 nM 
heterotrimeric G protein for approximately 500 s. The activation was started by adding 6 nM 
β1AR and 10 μM GTPγS, and the fluorescence intensity was monitored for a further 1 h. For 
experiments in the presence of an agonist, the concentrated receptor stock solution (1.5 μM) 
was pre-incubated for 30 min at 4 °C with 40 μM isoprenaline, and the buffer during the 
measurements contained 2 μM of isoprenaline to maintain the saturation conditions for the 
receptor. 
  
 - 13 - 
Figure legends 
 
Figure 1: Ligand-induced 1H-15N chemical shift changes in the vicinity of the ligand binding 
pocket of β1AR. 
(a) Partial view of the β1AR-carvedilol crystal structure (4AMJ) showing valine residues (blue 
spheres) in the vicinity (< 8.5 Å) of the ligand (magenta sticks) binding site. 
(b) Chemical structures of the β1AR ligands used in this study. Ligand affinities derived from 
whole cell binding assays on the thermostabilized β36-m23 β1AR construct17 are indicated as 
pKD values. Similar pK values were measured for the TS-β1AR construct (Extended Data 
Table 1). 
(c, left) Ligand-induced response of V172(4.56) 1H-15N resonances. The black bar represents a 
scale of 0.1 ppm (1H) and 1 ppm (15N). The labels o, m, p indicate respectively ligands with 
ortho, meta, and para substitutions at the head group. 
(c, right) Partial view of the β1AR-carvedilol structure (4AMJ) showing the interaction 
network connecting V172(4.56) to S215(5.461), P219(5.50), I129(3.40), and F299(6.44). 
(d, left) Representation as (c, left) for the 1H-15N resonances of V314(6.59). Centers of 
resonances are indicated by circles. 
(d, middle) Correlation of a best-fit linear combination of the V314(6.59) chemical shifts 
(48.9 δ1H + 0.986 δ15N -488) to the ligand affinity pKD (Extended Data Table 1). 
(d, right) Partial view of the carvedilol (red, 4AMJ), dobutamine (orange, 2Y01), 
cyanopindolol (green, 2VT4 B), and isoprenaline (blue, 2Y03) complex structures showing the 
ligand-induced movement of V314(6.59). 
(e, left) Representation as (d, left) for the 1H-15N resonances of V125(3.36) and V103(2.65). 
(e, middle) Correlations of best-fit linear combinations of chemical shifts for V125(3.36) 
(-0.402 δ1H + 1.17 δ15N -132) and V103(2.65) (-336 δ1H -634 δ15N +7.64·104) to the ligand 
insertion depths and tail volumes (Extended Data Table 1), respectively. 
(e, right) Partial view of the carvedilol, dobutamine, cyanopindolol, and isoprenaline crystal  
structures (representation as d, right) showing the ligand-induced movement of V125(3.36), 
D121(3.32), and V103(2.65). 
Figure 2: Correlation of ligand-induced chemical shift changes at the TS-β1AR intracellular 
side with Gs efficacy.  
(a, top) Response of the V226(5.57) 1H-15N resonance to various ligands (color coding as in 
Figure 1). The centers of resonances are indicated by circles. The 1H-15N resonances fall on 
one line from atenolol (antagonist) over apo to alprenolol (partial agonist), carvedilol 
(antagonist), cyanopindolol (partial agonist), dobutamine (full agonist) and isoprenaline (full 
agonist). 
(a, bottom) Correlation of a best-fit linear combination of the V226(5.57) chemical shifts 
(-515 δ1H -31.7 δ15N +8.41·103) in different ligand complexes to their efficacy for the Gs 
signaling pathway17. 
(b, top) Overlay of TM5 and TM6 backbones of thermostabilized β1AR in antagonist- (blue, 
PDB code 4AMJ) and agonist-bound (green, PDB code 2Y03) form. The agonist does not 
induce detectable helix movements. 
(b, bottom) TM5 and TM6 backbone movements upon activation in human β2AR. The overlay 
of inactive (blue, PDB code 2RH1) and G protein-bound β2AR (magenta, PDB code 3SN6) 
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structures shows the large bend of TM6 along with the smaller conformational change of TM5 
upon activation. Hydrogen bonds 5.57-HN···5.53-O and 5.61-HN···5.57-O are indicated by 
dashes. According to the behavior of the 1HN chemical shifts of V226(5.57) and V230(5.61) in 
TS-β1AR, these hydrogen bonds expand in an efficacy-dependent manner during agonist 
binding. 
(c) Response of the 1H-15N resonances for V226(5.57), V230(5.61), V298(6.43), and 
V280(6.25) to various ligands. For clarity, only the centers of resonances are depicted as 
circles with color coding as in Figure 1. The black bar represents a scale of 0.1 ppm and 1 ppm 
for the 1H and 15N chemical shifts, respectively. The schematic representation of the receptor 
indicates the locations of the respective valine residues at the cytoplasmic sides of TM5 and 
TM6 within the helical bundle of β1AR. 
 
Figure 3: Experimental detection of allosteric signaling pathways using the NMR response to 
ligand binding and point mutations at different backbone sites. 
(a) Combined 1H, 15N chemical shift deviations [Δδ = (Δδ1H2/2 + Δδ15N2/50)1/2] of valine 
resonances observed upon ligand binding or induced by the indicated point mutations. For 
ligand binding, the three pairwise deviations Δδ were calculated between the apo, atenolol-, 
and isoprenaline-bound forms of TS-β1AR. The maximum of these deviations is shown. For 
the reverse mutants, deviations Δδ are shown relative to TS-β1AR for their apo (black), 
atenolol- (cyan), and isoprenaline-bound (blue) bound forms. Valines within 10 Å from the Cα 
atom of the mutated amino acid are shown on a grey background. Distances were calculated 
using the coordinates of the thermostabilized β1AR (PDB code 4BVN). A red line marks a cut-
off value Δδ of 0.05 ppm for significant chemical shift deviations. 
(b) Topology of the signaling network determined from point mutations (left) and ligand 
binding (right). Signal paths were identified by chemical shift deviations Δδ  larger than 0.05 
ppm induced by these two perturbations (panel a). Signal paths to valines within 10 Å from 
the ligand or point mutation (i.e. localized conformational changes) are indicated as dashed 
lines, and those beyond 10 Å (long-range conformational changes) as solid lines. The ligand 
signals broadly towards all helices but TM1. In contrast, the network determined by the point 
mutations is more localized and connects TM3 to TM4/5, TM5 to TM3/4/6, and TM7 to 
TM2/3. The latter network appears to be divided into two subnetworks involving TM3/4/5/6 
and TM2/7. 
(c) Long-range allosteric signal paths identified from ligand binding or point mutations 
(Figure 3a and b) indicated on schematic β1AR representations showing the involved TMs. 
Helices are color-coded according to panel b. 
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Extended Data figure and table legends 
Extended Data Figure 1: Position of valine residues in the thermostabilized mutant TS-
β1AR. 
(a) Schematic representation of secondary structure and amino acid sequence of TS-β1AR. As 
compared to the wild type, the TS-β1AR has truncations at the N- and C-termini and the 
intracellular loop (ICL3) as well as nine thermostabilizing point mutations (color coded green) 
and three additional point mutations (color coded yellow). Valines labeled with 15N are 
indicated by bold circles for assigned (blue) and unassigned (grey) residues. 
(b) Structure of β1AR in complex with carvedilol (PDB code 4AMJ). The protein backbone 
and carvedilol are shown in ribbon and red stick representation, respectively. The individual 
valines are depicted as spheres (blue: assigned, grey: not assigned) labeled by residue number. 
(c) Full 1H-15N TROSY spectra of apo TS-β1AR and all investigated ligand complexes. The 
ligand chemical structures are shown as inserts. Resonances are marked with assignment 
information (black: firm, cyan: tentative). 
 
Extended Data Figure 2: Effect of ligand head group substitution on hydrogen bond network 
involving V172(4.56) in β1AR. 
(a) Sequence alignment of turkey β1AR and human adrenoreceptors around position 4.56 in 
TM4 showing the conserved proline at position 4.60. 
(b) Schematic representation of the hydrogen bond network between TM4 and TM5 involving 
V172(4.56) in β1AR. The hydrogen bond network (orange dotted lines) originates at the 
carbonyl of V172(4.56) and connects to TM5 via two water molecules (w1 and w2, red 
asterisks).  
(c, left) Phi and psi dihedral angles (averages and standard deviations in case of multiple 
chains) in TM4 between residues 4.48 and 4.61 for different complexes of β1AR (ligand, PDB 
code [chain]: carvedilol, 4AMJ [A,B]; cyanopindolol, 2VT4 [B,D] and 4BVN [A]; 
dobutamine, 2Y00 [A,B] and 2Y01 [A,B]; isoprenaline, 2Y03 [A,B]). V165(4.49) and 
V172(4.56), for which 1H-15N resonances could be observed, are shown on a green and red 
background, respectively. 
(c, right) Average of the 1H-15N resonance positions for V165(4.49, green) and V172(4.56, 
red). The phi and psi values of V172(4.56) are distorted from the normal helical angles due to 
the loss of the intra-helical hydrogen bond to P176(4.60). Together with the loss of the 
canonical hydrogen bond, this strongly shifts both the 1H and 15N chemical shifts of 
V172(4.56) towards smaller ppm values relative to V165(4.49), which has normal, helical phi 
and psi angles. 
(d) Partial views of the crystal structures of the carvedilol complex (PDB code 4AMJ), the 
isoprenaline complex (PDB code: 2Y03) and a docking model of the atenolol complex based 
on the cyanopindolol complex crystal structure (PDB code 4BVN). In the carvedilol complex, 
one water molecule (w2) forms a hydrogen bond network between the carbonyl oxygen of 
V172(4.56) and the side chains of S211(5.43) and S215(5.461). In the isoprenaline complex, 
the side chains of S211(5.43) and S215(5.461) are rotated and form hydrogen bonds to the 
catechol hydroxyl groups of isoprenaline. In this structure, no water molecule is observed at 
the equivalent position of w2. In the atenolol complex, the para-substituted acetamide of the 
ligand head ring (dashed circle) inserts between S211(5.43) and S215(5.461) and disturbs the 
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interface between TM3 and TM5 near V172(4.56) (solid circle). 
 
Extended Data Figure 3: Response to various ligands for all assigned valine 1H-15N 
resonances in TS-β1AR. Color coding as in Extended Data Figure 1: cyan (atenolol), blue 
(isoprenaline), orange (dobutamine), purple (alprenolol), red (carvedilol), green 
(cyanopindolol), black (apo receptor). For clarity the centers of resonances are marked by 
circles. Firmly (tentatively) assigned residues are marked in black (cyan). 
 
Extended Data Figure 4: Evidence for micro- to millisecond dynamics at the ligand 
entry/exit pathway. (Left) Region of the 1H-15N TROSYs showing the V314(6.59) 1H-15N 
resonance of TS-β1AR in the apo and various ligand-bound forms. The resonances of the apo 
and atenolol-bound forms are severely broadened in the 15N dimension indicative of backbone 
dynamics in the micro- to millisecond range. The broadening is not observed for the other 
more tightly binding ligands. The resonances for the low affinity ligands, atenolol, 
isoprenaline and dobutamine, and for the high affinity ligands, alprenolol, carvedilol and 
cyanopindolol cluster at different positions. Interestingly, the resonance of the apo form 
clusters with the high affinity ligands, indicative of a similar backbone conformation. 
(Right) 15N and 1H line widths of the V314(6.59) resonance for the apo and ligand-bound 
forms of TS-β1AR. 
 
Extended Data Figure 5: Isoprenaline-induced activation of Gαi1β1γ1 by β1AR mutants. G 
protein activation was measured by the change in tryptophan fluorescence upon exchange of 
GDP for GTPγS in the Gα subunit of the heterotrimeric G protein. The figure shows the time 
courses of tryptophan fluorescence after the addition of different mutant forms of TS-β1AR in 
nanodiscs and GTPγS to the heterotrimeric G protein in the presence (red) and absence (black) 
of the agonist isoprenaline. The increase in fluorescence intensity at time t = 0 is caused by the 
additional fluorescence of the receptor, the nanodisc scaffold protein and the ligand. For the 
active mutant TS-β1ARA227Y/L343Y, this initial rise is followed by an exponential fluorescence 
increase due to the activation and dissociation of the G protein. 
The rate of the Gαi activation by TS-β1ARA227Y/L343Y (half life ~290 s at 6 nM receptor) is 
approximately 4 times slower than for the activation by rhodopsin (half life ~400 s at 1 nM 
receptor) using the same assay. This assumes that the Km of Gαi for TS-β1ARA227Y/L343Y is of the 
same scale as for rhodopsin (8.6 nM) and therefore significantly below the (saturating) 
concentration of Gαi (100 nM). Each mutant was measured three times except for TS-
β1ARA227Y/L343Y that was measured four times. Representative fluorescence curves from single 
experiments are shown. 
 
Extended Data Figure 6: Observed NMR effects of the reverse mutations of TS-β1AR 
towards the native β1AR sequence. 
(a) 1H-15N TROSY spectra of TS-β1AR and several reverse single and double mutants in 
complex with either atenolol (cyan) or isoprenaline (dark blue). Resonances are marked with 
assignment information (black: definite, cyan: tentative). 
(b) Enlarged regions of the 1H-15N correlation spectra showing only the resonance positions of 
V226(5.57) and V280(6.25) for all mutants in both ligand-receptor complexes. The black bar 
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represents 0.1 ppm in 1H and 1 ppm in 15N. For all mutants, the resonances for V226(5.57) 
show efficacy-related chemical shift changes between atenolol (diamonds) and isoprenaline 
(circles). For the A227Y mutants TS-β1ARA227Y (green), TS-β1ARV129I/A227Y (orange) and TS-
β1ARA227Y/L343Y (cyan), the 1H-15N resonances of V226(5.57) also exhibit an overall shift due to 
a ring current effect from the introduced Y227(5.58) side chain, which has no structural 
significance. However, the V129I mutants TS-β1ARV129I (red) and TS-β1ARV129I/A227Y (orange) 
exhibit further 1H-15N shifts towards a more active (i.e. bent) state of TM5 relative to the 
mutants that carry the V129(3.40) residue. For all mutants, the V280(6.25) resonances fall 
basically in identical positions and show no changes between atenolol and isoprenaline. 
 
Extended Data Figure 7: Binding of NB80 to agonist-activated TS-β1ARA227Y/L343Y. 
(a) Sequential addition of isoprenaline (1 mM, blue), NB80 (120 μM, red), and cyanopindolol 
(1 mM, green) to TS-β1ARA227Y/L343Y (120 μM) followed by 1H-15N TROSY spectra. Addition 
of an equimolar amount of NB80 changes the spectrum drastically. Except for few resonances 
(62, 89, 102, 103, 172, 280 and 326), the assignments are not transferable from the 
isoprenaline complex. The addition of cyanopindolol to this mixture apparently replaces 
isoprenaline in the receptor and drives the spectrum to the purely cyanopindolol-bound form. 
These results indicate that TS-β1ARA227Y/L343Y can be activated, but that the fully active state 
requires stabilization with a G protein-like partner at the intracellular site. 
(b) Changes in isoprenaline affinity of β1AR induced by NB80 binding. The isoprenaline 
affinity was assayed for TS-β1ARA227Y/L343Y (green) and the truncated native turkey β1AR 
receptor (tβtrunc, blue)17 by radio-ligand competition using 3H-dihydroalprenolol in the  
presence of saturating amounts of NB80 (10 μM) or its absence. For TS-β1ARA227Y/L343Y and 
tβtrunc the apparent affinity increases by two log units in the presence of NB80, whereas no 
change occurs for TS-β1AR. Data points are shown as mean and standard deviation of three 
independent experiments for each condition. 
(c) Combined 1H and 15N chemical shift changes (Δδ = (Δδ1H2/2 + Δδ15N2/50)1/2) between the 
isoprenaline-TS-β1ARA227Y/L343Y and the NB80-isoprenaline-TS-β1ARA227Y/L343Y complexes as a 
function of residue number. Except for the few assigned peaks in the NB80-isoprenaline-TS-
β1ARA227Y/L343Y complex, chemical shift deviations are calculated as the minimal difference 
from the isoprenaline peak position to the nearest peak position in the isoprenaline-NB80 
complex. Note that these minimal chemical shift deviations present a lower boundary for the 
deviations that could be obtained from a full assignment of the isoprenaline-NB80 complex. 
Peak deviations are color-coded in red (≥0.2 ppm), orange (0.2–0.05 ppm), blue (<0.05 ppm), 
and grey (ambiguity from peak overlap). 
(d) Representation of the chemical shift response to nanobody binding given in (c) on the 
structure of β1AR. Valines in TM1 and TM7 do not show a large chemical shift response. Due 
to overlap the response for V280(6.25) in TM6 is unclear. Valines in TM2 show a strong 
response around the sodium binding region near residue D87(2.50), but valines at its 
extracellular side are not responsive. In general, valine resonances at the extracellular sides of 
TM3-6 are severely shifted. This indicates that the NB80 binding at the intracellular side has a 
long-range effect on the extracellular side, near the ligand binding site. 
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Extended Data Table 1: Pharmacological and geometrical properties of the β1AR ligands 
used in this study 
 
 pharmacology  geometry 
 pKD 
b36-m23* 
pKi 
TS-β1AR† 
pIC50 
TS-β1AR‡ 
Gs efficacy 
tβtrunc§ 
 insertion 
depth|| 
tail volume¶ 
cyanopindolol 10.01 ± 0.11 >8.4 ± 0.3# >8.1 ± 0.1# 39 ± 1  7.22 90.11 
carvedilol 8.72 ± 0.09 >8.3 ± 0.3# >7.9 ± 0.1# 12 ± 0.4  7.62 163.47 
alprenolol 7.35 ± 0.07 7.6 ± 0.3 7.2 ± 0.1 31 ± 2  7.25 73.87 
dobutamine 5.49 ± 0.03 5.0 ± 0.3 4.6 ± 0.1 112 ± 7  8.46 170.34 
isoprenaline 5.16 ± 0.05 4.9 ± 0.3 4.6 ± 0.2 100  7.92 73.87 
atenolol 4.29 ± 0.11 5.0 ± 0.3 4.6 ± 0.2 2.1 ± 1  ND✩ 73.87 
 
* Values for binding affinity correspond to the β36-m23 construct, which contains C- and N-
terminal deletions and six thermostabilizing mutations10. The pKD = -log KD [M] was obtained 
from 3H-CGP12177 whole cell binding assays in stably expressed CHO cells17. 
† pKi values were obtained from the pIC50 values given in column 3 by adding log(1+[lig]/KD) 
= 0.366 as a correction for the concentration of the 3H-dihydroalprenolol (3H-DHA) ([lig] = 
20 nM) and its determined dissociation constant (KD = 15.1 ± 7 nM, see Methods). Errors are 
obtained by error propagation from the errors of the pIC50 values and KD. 
‡ pIC50 values were determined by the radioligand inhibition assay described in the Methods 
section using 3H-DHA. Data are given as mean and standard deviation of three independent 
experiments. 
§ Values for efficacy towards Gs-mediated signaling as determined by adenylyl cyclase 
activation of the truncated native turkey β1AR receptor (tβtrunc)17. The efficacies are indicated 
as the percentage of the (maximal) isoprenaline response obtained from 3H-cAMP 
accumulation assays in CHO cells. 
|| The insertion depth [Å] of the ligand was taken as the distance between the β-carbon atom of 
the ligand amino group and the amide nitrogen atom of V125 (V117 for β2AR) in the crystal 
structures of turkey β1AR in complexes with isoprenaline (PDB ID: 2Y03), dobutamine (PDB 
ID: 2Y00), carvedilol (PDB ID: 4AMJ), and cyanopindolol (PDB ID: 4BVN) as well as of 
human β2AR in complex with alprenolol (PDB ID: 3NYA). 
¶ The tail volumes [Å3] were calculated by the Molinspiration Property Calculation Service 
(http://www.molinspiration.com/cgi-bin/properties) for the tail group including the amino 
moiety. 
# The pKi and pIC50 are limited by the KD and concentration of the radioactive tracer ligand as 
well as by the concentration of the receptor in the competition assay. 
✩ Not determined, no crystal structure available. 
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Extended Data Table 2: Sequence-specific assignment 1H-15N valine resonances 
Assigned 
residue 
Position Point 
mutation 
Spectra with ligands Further 
information 
V62 1.53 V62A Ate, Apo, Alp  
V90 2.53 V90A Ate, Alp, Car, Cya HN(CO) 
V94 2.56 V94A Alp, Car, Cya  
V102 2.54 V102A Ate, Apo, Alp, Iso, Dob, Car, Cya  
V122 3.33 V122A Alp, Car, Cya  
V125 3.36 V125A/I Alp(A), Car(A), Ate(I), Apo(I)  
V129 3.40 V129I Ate  
V134 3.45 V134A Ate  
V160 4.44 V160A Ate  
V172 4.56 V172A Ate, Alp Pred 
V202 ECL V202A Alp Pred 
V226 5.57 V226A Alp, Car, Cya  
V230 5.61 V230A Alp  
V280 6.25 V280A Alp, Car, Cya  
V298 6.43 V298A Ate HN(CO) 
V314 6.59 V314A Alp, Car, Cya  
V326 7.36 V326A Alp  
V89 2.52 - Ate, Apo, Alp, Iso, Dob, Car, Cya HB, NM 
V95 2.57 - Ate, Apo, Alp, Iso, Dob, Car, Cya HB, NM, HN(CO) 
V103 2.65 - Ate, Apo, Alp, Iso, Dob, Car, Cya HB, NM, HN(CO) 
V165 4.49 - Ate, Apo, Alp, Iso, Dob, Car, Cya NM 
 
Ate: atenolol, Alp: alprenolol, Iso: isoprenaline, Dob: dobutamine, Car: carvedilol, Cya: 
cyanopindolol 
HN(CO): information from 2D-filtered HN(CO) of 15N,13C-Gly,Val, 15N-Leu labeled receptor 
Pred: ShiftX2 15N chemical shift prediction31 
HB: expected 1HN shift based on hydrogen bond length analysis 
NM: peak shift due to mutation of neighboring residue 
Assignments for V89(2.52), V95(2.57), V103(2.65), V122(3.33), and V165(4.49) are 
tentative. V51(1.42), V52(1.43), V56(1.47), V60(1.51), V309(6.54), V312(6.57), and 
V320(ECL) have not been assigned. 
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Extended Data Table 3: Summary of the NMR response to ligands, G protein activation 
and NB80 binding data for the original TS-β1AR construct and various reverse mutants 
towards the native β1AR sequence 
 
mutant name 
 residue  V226 
response∗ 
V280 
response∗ 
G protein 
activation† 
NB80 
binding‡ Tm [˚C]
§ 
129 227 343 
original TS-β1AR V A L + - - 
- 
(4.55/4.52) 58.9 +/– 0.6 
TS-β1ARV129I I|| A L + - - N.D.¶ 58.6 +/– 0.2 
TS-β1ARA227Y V Y L + - - - 54.9 +/– 0.1 
TS-β1ARL343Y V A Y + - - - 54.7 +/– 0.3 
TS-β1ARV129I/A227Y I Y L + - - N.D. 54.4 +/– 0.1 
TS-β1ARA227Y/L343Y V Y Y + - + 
+ 
(4.36/6.32) 
47.8 +/– 0.2 
 
∗ determined from the shifts of the 1H-15N resonances in response to binding of atenolol and 
isoprenaline (see Extended Data Figure 6B). 
† determined from the Gαi1β1γ1 activation assay described in Extended Data Figure 5. 
‡ determined from NMR experiments by mixing of isoprenaline-activated TS-β1AR with 
NB80. The 1H-15N spectra are shown for TS-β1ARA227Y/L343Y in Extended Data Figure 7. The 
spectra of the other TS-β1AR mutants showed no response to addition of NB80 up to 
equimolar concentrations of ~100 µM for both proteins. Values in parentheses show pIC50 for 
isoprenaline binding in the absence or presence of NB80, respectively (see Extended Data 
Figure 7). 
§ melting temperature Tm of the apo form receptor determined by the CPM thermal shift assay. 
|| native residues are highlighted in bold. 
¶ not determined. 
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Backbone NMR reveals allosteric signaling networks in the β1-adrenergic 
receptor 
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Text 1. Estimation of hydrogen bond length change from 1HN chemical shift change and 
uncertainty of crystal structure coordinates 
 
The correlation between hydrogen bond length dHO  and amide proton chemical shift !H N  can 
be expressed as1 
 
!H N =19.2 !Å3 !dHO"3 " 2.3  
 
where !H N  is given in ppm and dHO  is the distance between amide hydrogen and carbonyl 
oxygen atoms. Taking the derivative relative to the distance dHO  yields 
 
d!H N
ddHO
= !3"19.2 "Å3 "dHO!4  
 
A finite small change !dHO in hydrogen bond distance can then be calculated from a finite 
small chemical shift change !!H N as 
 
!dHO "
#dHO4
3$19.2 $Å3 !!H
N  
 
Using !!H N = "0.2  for the change from the atenolol-bound to the isoprenaline-bound V226 
resonances and dHO = 1.9 Å then yields a value ΔdHO = 0.045 Å. 
 
The uncertainty of crystal structure coordinates can be estimated from the Cruickshank 
diffraction-component precision index (DPI)2. For the currently highest resolution GPCR 
structure (human δ opioid receptor3, 1.80 Å resolution), the DPI is 0.127 Å, which is larger 
than the small H-bond distance change detected by NMR. 
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